ROLE OF PERIPARTUM CARDIOMYOPATHY ON MATERNAL MORTALITY DURING THE THIRD TRIMESTER OF PREGNANCY
European Journal of Clinical Pharmacy · 27.12.2025 · 7 · 8858-8864
DOI: 10.61336/ejcp/25-08-596 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 27.12.2025.
Abstract (Originalsprache)
Objective
To determine the frequency of maternal mortality during the third trimester among women diagnosed with peripartum cardiomyopathy (PPCM) at a tertiary care hospital in Larkana and assess its association with maternal characteristics.
Methods
This descriptive cross-sectional study was conducted at the Department of Obstetrics and Gynecology, SMBBMU, Larkana, Pakistan, This research was conducted in a duration of Four months from 15th June 2025- to 15th October 2025, following ethical approval from the Institutional Ethical Review Committee and College of Physicians and Surgeons Pakistan (CPSP). A total of 135 women aged 18–40 years with gestational age ≥28 weeks diagnosed with PPCM were enrolled through non-probability consecutive sampling. Data regarding demographic, obstetric, clinical, laboratory, and echocardiographic characteristics were collected using a structured proforma. PPCM was diagnosed based on heart failure symptoms, NT-pro-BNP >500 pg/mL, left ventricular ejection fraction (LVEF)
Zitieren
APA
(2025). ROLE OF PERIPARTUM CARDIOMYOPATHY ON MATERNAL MORTALITY DURING THE THIRD TRIMESTER OF PREGNANCY. European Journal of Clinical Pharmacy, 7, 8858-8864. https://doi.org/10.61336/ejcp/25-08-596
Vancouver
ROLE OF PERIPARTUM CARDIOMYOPATHY ON MATERNAL MORTALITY DURING THE THIRD TRIMESTER OF PREGNANCY. European Journal of Clinical Pharmacy. 2025;7:8858-8864. doi:10.61336/ejcp/25-08-596
BibTeX
@article{euvimed2025,
title = {ROLE OF PERIPARTUM CARDIOMYOPATHY ON MATERNAL MORTALITY DURING THE THIRD TRIMESTER OF PREGNANCY},
journal = {European Journal of Clinical Pharmacy},
year = {2025},
volume = {7},
pages = {8858--8864},
doi = {10.61336/ejcp/25-08-596}
}
EUVIMED